A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Completed · Phase 2 · Has a placebo group

Conditions studied: Lower Urinary Tract Symptoms (LUTS)

In brief

A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

Key facts

Study ID

NCT00947882

Run by

Ferring Pharmaceuticals

People needed

404

Starts

2009-08-01

Expected to finish

2011-06-01

Last updated by the study team

2015-06-08

Who can join

Age: 50 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent obtained before any trial-related activity is performed
• Men, aged 50 or older
• Clinical signs and symptoms of BPH for ≥6 months
• Moderate to severe LUTS at screening, as defined by International Prostate Symptom Score (IPSS) ≥13
• An IPSS QoL score of ≥3 at screening
• Prostate specific antigen (PSA) at screening ≤10 ng/mL (responsibility of the Investigator to rule out prostate cancer when PSA is >4 ng/mL, except in the USA where patients with a PSA >4 and ≤10 ng/mL should undergo a prostatic biopsy or have a negative prostatic biopsy within 12 months prior to participation in the trial)
• Maximum urinary flow (Qmax) ranging between 5 to 15 mL/second with a minimum voided volume >125 mL at screening

You may not qualify if…

• Post void residual volume (PVR) >250 mL
• Stone in the bladder or urethra causing symptoms
• Acute or chronic prostatitis
• Interstitial cystitis / painful bladder syndrome
• Acute or recurrent urinary tract infections
• History of acute urinary retention (AUR)
• Lower urinary tract instrumentation (including prostate biopsy) within 30 days of dosing at Visit 2
• Clinical evidence of any of the following urinary tract conditions:
• Mullerian duct cysts
• Atonic, decompensated, or hypocontractile bladder
• Detrusor-sphincter dyssynergia (contraction of the detrusor without sphincter relaxation)
• History of any of the following pelvic conditions:
• Pelvic surgery or any other pelvic procedure, including radical prostatectomy, pelvic surgery for removal of malignancy, or open lower colonic or rectal surgery
• Pelvic radiotherapy
• Any prior surgical procedure of the urinary tract, including minimally invasive LUTS/BPH therapies
• Lower tract malignancy or trauma
• Clinically significant microscopic haematuria at screening
• History of significant renal insufficiency, defined as receiving renal dialysis or having an estimated creatinine clearance <30 mL/minute at screening
• Systolic blood pressure >180 or <90 mmHg or diastolic blood pressure >110 or <50 mmHg at screening or malignant hypertension
• Any causes other than BPH, which may affect evaluation of symptoms of urine flow (e.g. neurogenic bladder, bladder neck contracture, urethral stricture, and bladder malignancy) as judged by the Investigator
• Use of any prohibited therapies
• Elevated liver function tests at screening:
• Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) >2 times the upper limit of normal
• Total bilirubin >1.5 times the upper limit of normal
• QTc interval on the screening ECG >450 ms, or a family history of long QT syndrome

Where it is running

• Urology Centers of Alabama, PC — Homewood, Alabama, United States
• Coastal Clinical Research Inc — Mobile, Alabama, United States
• California Professional Research — Newport Beach, California, United States
• Genitourinary Surgical Consultants — Denver, Colorado, United States
• Urology Associates , PC — Englewood, Colorado, United States
• South Florida Medical Research — Aventura, Florida, United States
• Winter Park Urology Associates — Orlando, Florida, United States
• Pinellas Urology Inc — St. Petersburg, Florida, United States
• Florida Urology Partners — Tampa, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• Weill Cornell Medical College New York Presbyterian — New York, New York, United States
• Hudson Valley Urology, PC — Poughkeepsie, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Patient Priority Clinical Sites, LLC — Cincinnati, Ohio, United States
• Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States
• Middelheim Antwerp — Antwerp, Belgium
• UZ Brussel — Brussels, Belgium
• Can-Med Clinical Research Inc — Victoria, British Columbia, Canada
• Dr Steinhoff Clinical Research — Victoria, British Columbia, Canada
• Male/Female Health and Research Centre — Barrie, Ontario, Canada
• Bramalea Medical Centre — Brampton, Ontario, Canada
• Brandford Urology Research — Brantford, Ontario, Canada
• Guelp Urology — Guelph, Ontario, Canada
• Centre for Applied Urological Research — Kingston, Ontario, Canada
• Investigational Site — North Bay, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.